Neuroprotective effects of infliximab in experimental spinal cord injury

Kurt, Gökhan; Ergun, Ertan; Cemil, Berker; Börcek, Alp Özgün; Börcek, Pelin; Gülbahar, Özlem; Çeviker, Necdet

doi:10.1016/j.surneu.2008.01.038

Cited by 41 publications

(38 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…36 Kurt et al reported that spinal cord ischemic injury (SCI) reportedly increases MDA levels and that treatment with infliximab decreases the MDA levels in the spinal cord tissue of rats with SCI. 37 Furthermore, Guven et al demonstrated that treatment of I/R injury with infliximab decreased SOD activity and increased GSH levels in spinal cord tissue. In our study, infliximab tended to increase SOD activity and GSH levels.…”

Section: Discussionmentioning

confidence: 99%

Protective Effect of Infliximab on Ischemia/Reperfusion-Induced Damage in Rat Kidney

et al. 2012

View full text Add to dashboard Cite

Objective: To investigate the protective effect of infliximab on ischemia-reperfusion (I/R) injury of the rat kidney. Methods: Twenty-eight male Wistar albino rats were divided into four groups: sham-operated, I/R, I/R with infliximab administered before ischemia [I/R þ infliximab (bi)], and I/R with infliximab administered before reperfusion [I/R þ infliximab (br)]. After a right nephrectomy to produce damage, the left renal vessels were occluded for 60 min, followed by 24-h reperfusion in rats. Changes in the rat kidney were observed by measuring the tissue levels of malondialdehyde (MDA), myeloperoxidase (MPO), glutathione (GSH), and superoxide dismutase (SOD) and by evaluating hematoxylin-eosin (H&E)-stained and periodic acid-Schiff (PAS) sections. Results: The MDA and MPO levels in the I/R group were significantly higher than in the other groups (p < 0.05), and the SOD and GSH levels in the I/R þ infliximab (bi) and I/R þ infliximab (br) groups were significantly higher than in the I/R group (p < 0.05). However, histological examination revealed that the I/R þ infliximab (bi) group and the I/R þ infliximab (br) group had significantly fewer tubular changes and interstitial inflammatory cell infiltration than the I/R group. Conclusion: These results show that infliximab may protect against I/R injury in the rat I/R model.

show abstract

Section: Discussionmentioning

confidence: 99%

Protective Effect of Infliximab on Ischemia/Reperfusion-Induced Damage in Rat Kidney

et al. 2012

View full text Add to dashboard Cite

show abstract

“…[3,4,6,10,55,56,59, 62,70,73,80,82,84,85,107,169,170] • Spinal cord injury [7,143,144,[146][147][148][149][150] • Traumatic brain injury [136] • Stroke [137][138][139][140] …”

Section: Box 2 Perispinal Etanercept: Key Therapeutic Targets In Neumentioning

confidence: 99%

“…Multiple basic science studies have implicated TNF in the neuronal injury that follows spinal cord trauma [141][142][143]. In addition to the studies implicating TNF in its pathogenesis, accumulating basic evidence documents improvement in spinal cord injury (SCI) by anti-TNF biologics [144][145][146].…”

Section: Perispinal Etanercept: Additional Therapeutic Targets In Neumentioning

confidence: 99%

Perispinal etanercept: a new therapeutic paradigm in neurology

Tobinick

2010

Expert Review of Neurotherapeutics

107

View full text Add to dashboard Cite

“…Serum sickness-like reactions were observed in some Crohn's disease patients 3 to 12 d after therapy was reinitiated following an extended period without infliximab. Fever, rash, headache, sore throat, myalgia, polyarthralgias, hand and facial oedema and dysphagia were also associated with a marked increase in antibodies to infliximab [58,66,67] . However, the effects of infliximab in reducing renal ischaemic injury have not been clearly determined and this manipulating agent may have a potential role in DCD, ECD kidney transplantation.…”

Section: Infliximabmentioning

confidence: 96%

“…In vivo, infliximab is indicated for the treatment of rheumatologic, gastrointestinal, dermatologic, and chronic ocular diseases [51,57] . The role of infliximab has been shown to improve I/R injury in spinal injury models [51,58] and cardiac injury models [59,60] . Guven et al [51] demonstrated that the use of infliximab significantly reduced vascular proliferation, oedema and neuron loss following I/R injury and concluded that the agent may protect the spinal cord against injury in a rabbit I/R model.…”

Section: Infliximabmentioning

confidence: 99%

Ischaemic/reperfusion injury: Role of infliximab

Bagul¹

2012

WJT

View full text Add to dashboard Cite

Ischaemia/reperfusion (I/R) injury is an underlying complex interrelated patho-physiological process which effects the outcome of many clinical situations, in particular transplantation. Tumor necrosis factor (TNF)-α is a pleiotropic inflammatory cytokine; a trimeric protein encoded within the major histocompatibility complex which plays a pivotal role in this disease process. This review is based at looking into an update, particularly the new insights in the mechanisms of action of TNF antagonist such as infliximab. Infliximab may thus play a dual role in the field of transplantation where it might not only down regulate the I/R injury, it may also have a beneficial role in the reduction of acute rejection.

show abstract

Neuroprotective effects of infliximab in experimental spinal cord injury

Cited by 41 publications

References 45 publications

Protective Effect of Infliximab on Ischemia/Reperfusion-Induced Damage in Rat Kidney

Protective Effect of Infliximab on Ischemia/Reperfusion-Induced Damage in Rat Kidney

Perispinal etanercept: a new therapeutic paradigm in neurology

Ischaemic/reperfusion injury: Role of infliximab

Contact Info

Product

Resources

About